Azura Ophthalmics Announces Participation in the 2023 SVB Securities Global Biopharma conference
TEL AVIV, Israel & MELBOURNE, Australia, January 17, 2023–(BUSINESS WIRE)–Azura Ophthalmics Ltd.Today, Ophthalmic Keratolytics is a clinical-stage company that develops a new class of Ophthalmic Keratolytics to treat ocular surface diseases. It announced that its executive teams will hold 1×1 investor meeting during the Private Company Track at the 2023 SVB Securities Global Biopharma Conference. The meetings are being held from January 31 to February 2.
Contact conference representatives for more information and to schedule a meeting with the management.
Meibomian Gland Dysfunction
Meibomian Gland dysfunction is a progressive and chronic condition that causes blockage in the meibomian meibomian cells and alteration of expressed meibum quality. This can lead to gland atrophy. It is the leading cause for Dry Eye Disease and Contact Lens Discomfort.1,2 MGD is commonly characterized by terminal duct obstruction and/or qualitative/quantitative changes in the glandular secretion.3 These glandular problems are not treated by approved prescription medications. MGD, if left untreated can alter the tear film and cause additional ocular surface diseases like Dry Eye Disease. This can lead to corneal infections or corneal ulcers.
About AZR–MD-001
Azura’s lead clinical-stage drug candidate, AZR-MD-001, harnesses the power of selenium sulfide (SeS2In an easy-to use ophthalmic eye ointment, it is applied directly to the lower meibomian glands. The multi-modal mechanism that AZRMD-001 uses to treat Meibomian Gland Dysfunction and its ocular surface symptoms is believed to be multi-modal. It reduces the keratin protein bonds to ease the blockage.
AZRMD-001 is currently being tested to determine safety, efficacy, tolerability, and compliance in patients with MGD. Azura anticipates that AZRMD-001 0.5% will be subject to a second multi-center pivotal clinical trial in 2023.
About Azura Ophthalmics, Ltd.
Azura Ophthalmics has developed a new class of Ophthalmic Keratolytics using our deep knowledge of ocular surfaces diseases and drug design to treat underserved eye conditions. Our unique approach blends dermatologic and ophthalmologic solutions to harness the unique properties keratolytics. This allows us to address the root cause of many underserved ocular indications. We have a unique pipeline of chemical entities that we discovered internally, which allows us to create a portfolio of first in-class ophthalmic therapeutics to address significant unmet medical needs. Visit: www.azuraophthalmics.com Follow Azura on LinkedIn Twitter.
_________________________
Refer to
1. Milner, M. S., Beckman, K. A., Luchs, J. I., Allen, Q. B., Awdeh, R. M., Berdahl, J., Boland, T. S., Buznego, C., Gira, J. P., Goldberg, D. F., Goldman, D., Goyal, R. K., Jackson, M. A., Katz, J., Kim, T., Majmudar, P. A., Malhotra, R. P., McDonald, M. B., Rajpal, R. K., Raviv, T., … Yeu, E. (2017). Dysfunctional tear syndrome: dry eye disease and associated tear film disorders – new strategies for diagnosis and treatment. Current opinion in ophthalmology, 27 Suppl 1(Suppl 1), 3–47. https://doi.org/10.1097/01.icu.0000512373.81749.b7.
2. Foulks GN, Bran AJ. A clinical scheme to describe, diagnose, classify, and grade meibomian gland dysfunction. Ocul Surf. 2003;1:107-126.
3. Efron N, Jones L, Bron AJ, et al. The TFOS International Workshop on Contact Lens Problems: Report of Contact Lens Interactions with Ocular Surface and Adnexa Subcommittee. Invest Ophthalmol Vis Sci. 2013;54:TFOS98–TFOS122.
Visit businesswire.com to see the source version https://www.businesswire.com/news/home/20230117005976/en/
Contacts
Investor:
Ashwin Agarwal
Chief Financial Officer
949-439-1865
[email protected]
Media:
Tara Mulloy
MacDougall Advisors
781-235-3060
[email protected]